Rapid Adioponectin ELISA Kit
The Rapid Adiponectin ELISA Kit is For Research Use Only
Size: 1×96 wells
Standard Range: 7.8g/ml-500ng/ml
Incubation Time: 45 minutes
Sample Type: Serum, plasma, and cell culture supernates
Sample Size: 10 µl
Alternative Names: apM1, Acrp30, GBP28, and adipoQ
The Rapid Adiponectin assay is a sandwich ELISA designed for the quantitative detection of human adiponectin in samples in 1 hour. A mouse monoclonal antibody specific to human adiponectin has been pre-coated onto a micro-titre plate. The user pipettes standards and samples into the wells and any human adiponectin present is sandwiched by the immobilised antibody and a second horseradish peroxidase (HRP)-linked monoclonal antibody specific to human adiponectin that is co-incubated with the samples. After wash step to remove any unbound reagents, an HRP substrate solution is added and color develops in proportion to the amount of human adiponectin bound initially. The assay is stopped and the optical density of the wells determined using a microplate reader. Since the increases in absorbance are directly proportional to the amount of captured human adiponectin, the unknown sample concentration can be interpolated from a reference curve included in each assay.
High Sensitive Adiponectin ELISA Kit
Mouse Adiponectin ELISA Kit
Adiponectin, also known as apM1, Acrp30, GBP28 and adipoQ, is a circulating hormone predominantly produced from adipose tissue1. Many pharmacological studies demonstrated that this protein possesses potent anti-diabetic, anti-atherogenic and anti-inflammatory functions. Supplement of adiponectin protein can decrease blood glucose2, improve insulin sensitivity3, alleviate fatty liver4 and prevent atherosclerosis5. The protein is posttranslationally modified by hydroxylation and glycosylation6, and forms three different oligomeric complexes in the circulation7. Many clinical studies demonstrated that plasma adiponectin is an useful biomarker for metabolic syndrome, nonalcoholic steatohepatitis and certain type of cancers1. Decreased circulating levels of plasma adiponectin (‘hypoadiponectinaemia’) are associated with increased body mass index (BMI), decreased insulin sensitivity, less favourable plasma lipid profiles, increased levels of inflammatory markers and increased risk for the development of type 2 diabetes, hypertension, and coronary heart diseases. Low adiponectin concentrations were found to be predictive of a future reduction in insulin sensitivity and cardiovascular disorders. Administration of the anti-diabetic drugs thiazolidinediones (TZDs) raises circulating adiponectin levels8. In addition, low plasma adiponectin levels are also associated with nonalcoholic steatohepatitis (NASH) and certain types of cancers.
Typical Standard Curve